Loading
A phase 2 trial of Rusfertide in myeloproliferative neoplasms, run by Takeda, now recruiting.
A Study of Rusfertide in Japanese Adults With Polycythemia Vera is a phase 2 interventional study registered as NCT07648030 by Takeda, with 9 participants planned, started 2026-07-14 and due to reach its primary completion in 2027-10-28. Interventions recorded: Rusfertide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rusfertide, Peptide-drug & small-molecule-drug conjugates, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Peptide-drug & small-molecule-drug conjugates and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/